WASHINGTON, D.C., October 29, 2016 - In recognition and appreciation of Senator Patty Murray's (D-WA) efforts in the fight to end Alzheimer's the Alzheimer's Impact Movement (AIM) is supporting her re...

WASHINGTON, D.C., November 3, 2016 - The Alzheimer's Impact Movement (AIM) is celebrating the final decision by the Centers for Medicare & Medicaid Services (CMS) to improve access to care and support...

WASHINGTON, D.C., December 7, 2016 - Following action taken by the House of Representatives, the Senate today voted to pass the 21st Century Cures Act, which would secure additional funding at the...

The Alzheimer's Association and the Alzheimer's Impact Movement (AIM) are proud to support the bipartisan NAPA Reauthorization Act and the Alzheimer's Accountability and Investment Act. Introduced in...

This week, the Alzheimer's Association sponsored, and the Hill hosted, a discussion on accelerated approval with policymakers, experts and patient advocates. Through the Food and Drug Administration's...

Earlier this month, a $289 million increase in funding for Alzheimer's and other dementia research at the National Institutes of Health (NIH) was approved by Congress and signed into law by President...

For people living with mild cognitive impairment (MCI) due to Alzheimer's disease, the Centers for Medicare & Medicaid Services (CMS) proposal to sharply limit access to current and future treatments...

For people living with early-stage Alzheimer's disease like Mike Zuendel, the clock is ticking after the Centers for Medicare & Medicaid Services (CMS) draft decision that effectively denies access to...

This article originally appeared in the 2022 Impact Report. Become a member today to get access to additional exclusive content, meetings and insights into the Alzheimer's and dementia public policy...

The Centers for Medicare & Medicaid Services (CMS) issued a draft decision that essentially denies coverage of treatments targeting amyloid for Alzheimer's disease, including aducanumab, the first FDA...